1型糖尿病试验网:在疾病预测,预防和免疫治疗机制理解方面发挥领导作用
Laura M Jacobsen1, Jamie L Felton2, Brandon M Nathan3
1Departments of Pediatrics and Pathology, University of Florida Diabetes Institute, Gainesville, FL.
Diabetes care
|April 24, 2025
概括
1型糖尿病试验网 (TrialNet) 的研究已经导致了新的免疫疗法,延迟了1型糖尿病的发病. 目前正在进行的研究重点是早期干预,个性化治疗和1型糖尿病的社区参与.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 临床研究 临床研究
背景情况:
- 1型糖尿病试验网 (TrialNet),由国家糖尿病和消化和脏疾病研究所 (NIDDK) 于2001年建立,是一个全球研究网络.
- TrialNet研究1型糖尿病的发展,并旨在通过临床研究来延迟或预防这种疾病.
研究的目的:
- 审查NIDDK资助的TrialNet计划的主要发现,成就和未来方向.
- 突出TrialNet研究对1型糖尿病治疗和预防的影响.
主要方法:
- 进行了20多项干预,观察和机制导向的临床研究.
- 与数千名1型糖尿病患者及其家属合作.
- 利用机械学的发现来为正在进行和未来的试验设计提供信息.
主要成果:
- 成功开发和应用新的和重新定位的免疫疗法,用于第2期和第3期1型糖尿病.
- 有助于FDA批准了第一个疾病修饰疗法,以延迟1型糖尿病的发病.
- 生成的机理性见解推动了新型组合治疗的发展.
结论:
- 试验网已经显著提升了1型糖尿病的研究,导致疾病修饰疗法.
- 目前和未来的举措重点是早期试验,社区参与,多元化代表,个性化医疗和培训.
- 该计划继续在了解和打击1型糖尿病方面发挥关键作用.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Management and Pharmacotherapy
207
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
207
Pathophysiology of Diabetes
807
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
807
Diabetes: Symptoms, Diagnosis, and Complications
475
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
475
Insulin: Dosing Regimen and Adverse Effects
125
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
125


